Business
Medical Marijuana, Inc. Portfolio Investment Company Kannalife, Inc. Receives Patent in Australia for Its Novel Monotherapeutic Compounds to Treat CNS and PNS Disorders
Medical Marijuana, Inc. Portfolio Investment Company Kannalife, Inc. Receives Patent in Australia for Its Novel Monotherapeutic Compounds to Treat CNS and PNS Disorders.
About this update from Medical Marijuana, Inc.
[{"type":"text","content":"\n\n\n\nMedical Marijuana, Inc. Portfolio Investment Company Kannalife, Inc. Receives Patent in Australia for Its Novel Monotherapeutic Compounds to Treat CNS and PNS Disorders\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nMedical Marijuana, Inc. Portfolio Investment Company Kannalife, Inc. Receives Patent in Australia for Its Novel Monotherapeutic Compounds to Treat CNS and PNS Disorders\nPR Newswire\nSAN DIEGO, March 19, 2020\n\n\n\nSAN DIEGO, March 19, 2020 /PRNewswire/ -- Medical Marijuana, Inc. (OTC: MJNA) (the \"Company\"), the first-ever publicly traded cannabis company in the United States that launched the world's first-ever cannabis-derived nutraceutical products, brands and supply chain, announced today that its portfolio investment company Kannalife, Inc. (\"Kannalife\") (OTCQB: KLFE) has been issued Australian Patent AU2015204609B2 (the \"Patent\") specific to \"Novel Functionalized 1,3-Benzene Diols and their Method of Use for the Treatment of Hepatic Encephalopathy.\" With this Patent, Kannalife now holds seven patents across the globe.\n\"Medical Marijuana, Inc. and our portfolio of companies such as Kannalife are committed to widening knowledge and acceptance of cannabis and cannabinoid-related studies around the world,\" said Dr. Stuart Titus, CEO of Medical Marijuana, Inc. \"Kannalife is pushing forward that goal with new patents in six countries.\"\nKLS-13019 leads Kannalife's intellectual property estate of novel, monotherapeutic molecules (\"KLS Family\"), which are capable of acting as neuroprotective agents and have the potential to treat a range of diseases, including nervous system, oxidative stress, and neurodegenerative disorders.\n\"With this Patent, we are honored that so many jurisdictions have recognized our IP estate as novel and proprietary,\" said Dean Petkanas, CEO of Kannalife. \"We see this as an important step towards commercializing our lead drug candidate KLS-13019 in several markets in the future, including the Australian pharmaceutical market, which is expected to reach $32.1 billion in 2020 alone.\"\nOf th...